Amgen Inc. $AMGN Shares Sold by Kingsview Wealth Management LLC

Kingsview Wealth Management LLC cut its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 7.2% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 37,812 shares of the medical research company’s stock after selling 2,920 shares during the period. Kingsview Wealth Management LLC’s holdings in Amgen were worth $12,376,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of the business. Smith Chas P & Associates PA Cpas grew its position in shares of Amgen by 70.8% during the 4th quarter. Smith Chas P & Associates PA Cpas now owns 118,287 shares of the medical research company’s stock valued at $38,716,000 after acquiring an additional 49,013 shares during the period. Texas Capital Bank Wealth Management Services Inc grew its position in shares of Amgen by 7.7% during the 4th quarter. Texas Capital Bank Wealth Management Services Inc now owns 3,450 shares of the medical research company’s stock valued at $1,129,000 after acquiring an additional 248 shares during the period. Community Bank & Trust Waco Texas grew its position in shares of Amgen by 1.1% during the 4th quarter. Community Bank & Trust Waco Texas now owns 10,133 shares of the medical research company’s stock valued at $3,317,000 after acquiring an additional 113 shares during the period. Waystone Advisors LLC acquired a new stake in shares of Amgen during the 4th quarter valued at about $381,000. Finally, Geode Capital Management LLC grew its position in shares of Amgen by 7.8% during the 4th quarter. Geode Capital Management LLC now owns 14,303,294 shares of the medical research company’s stock valued at $4,665,822,000 after acquiring an additional 1,035,779 shares during the period. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Amgen

In related news, SVP Nancy A. Grygiel sold 1,237 shares of the company’s stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $323.73, for a total transaction of $400,454.01. Following the completion of the transaction, the senior vice president owned 7,009 shares in the company, valued at $2,269,023.57. This represents a 15.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.85% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on AMGN. Jefferies Financial Group began coverage on Amgen in a research report on Tuesday, March 10th. They set a “hold” rating and a $350.00 target price on the stock. Mizuho raised their target price on Amgen from $280.00 to $295.00 and gave the company an “outperform” rating in a research report on Tuesday, February 10th. Wells Fargo & Company raised their target price on Amgen from $375.00 to $390.00 and gave the company an “equal weight” rating in a research report on Thursday, March 19th. TD Cowen restated a “buy” rating on shares of Amgen in a research report on Wednesday, February 4th. Finally, Leerink Partners restated a “market perform” rating and set a $355.00 price target on shares of Amgen in a research report on Thursday, March 5th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, fourteen have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $355.19.

Amgen Stock Up 0.0%

AMGN opened at $336.06 on Thursday. Amgen Inc. has a twelve month low of $267.83 and a twelve month high of $391.29. The company has a quick ratio of 1.01, a current ratio of 1.26 and a debt-to-equity ratio of 5.65. The company has a 50-day moving average price of $343.32 and a 200 day moving average price of $345.27. The company has a market cap of $181.37 billion, a PE ratio of 23.39, a price-to-earnings-growth ratio of 3.37 and a beta of 0.44.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, topping the consensus estimate of $4.77 by $0.38. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The firm had revenue of $8.62 billion during the quarter, compared to the consensus estimate of $8.58 billion. During the same quarter in the prior year, the firm earned $4.90 EPS. The company’s revenue for the quarter was up 5.8% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Sell-side analysts expect that Amgen Inc. will post 22.37 earnings per share for the current fiscal year.

Amgen Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be given a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a dividend yield of 3.0%. The ex-dividend date is Friday, May 15th. Amgen’s dividend payout ratio is 70.15%.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.